Podcasts about Komet

Takt32 bei Deutschrap Plus im Interview

Es ist der erfolgreichste Hit in Deutschlands jemals: „Komet“ von Udo Lindenberg und Apache 207. Ein Song zweier Künstler, die aus völlig unterschiedlichen Welten kommen und doch ein perfektes Duo ergeben.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Ein Gespräch mit dem Golem.de-Redakteur Frank Wunderlich-Pfeiffer über vergangene und zukünftige Gefahren aus dem All - und wie wir sie verhindern können.

Velkommen indenfor til onsdagens Hattrick: Chido Obi Martin er kåret som Årets Komet 2025 – en pris vi uddeler her på Bold, og uafhængigt af hinanden har flere kilder peget på United-stjernefrøet som Danmarks største talent i øjeblikket.Og så er der kommet en afgørelse efter det heftige opgør mellem FCM og FCK, hvor røgbomber og smadrede toiletter stjal al opmærksomheden.Sidst, men ikke mindst, skal vi også forbi Mike Tullberg. Den eftertragtede danske træner har nemlig sikret sig et nyt job. Vært og produktion: Oliver Routledge Lyddesign: William DinesenSee omnystudio.com/listener for privacy information.

Udo Lindenbergs Fußabdruck wird einmal bleiben. Er ist jetzt ja schon ne Ikone, wunderbar schnoddrig, Urgestein. Und was ist mit uns Normalsterblichen? Hört mal rein bei Apache 207 und Udo Lindenberg: Komet.

In dieser Folge ist Alles anders! Statt Film, Serie oder Game haben wir uns dieses Mal nichts Geringeres als MUSIK als Thema ausgesucht, um gemeinsam mit Gitarrist André Gorjatschow und Mathematiker Aeneas Rooch vom ARD-Podcast "Fakt ab!" auf akustische Exkursion zu gehen: Welche berühmten Musiker:innen haben's auch wissenschaftlich raus? Welchen Lyrics solltet ihr faktisch lieber nicht über den Weg trauen? Und was haben Mathe und Metal gemeinsam? Wir haben euch dafür sogar extra eine Playlist zusammengestellt – in dieser Folge!

Die Themen in den Wissensnachrichten: +++ Grundeinkommen macht zufriedener +++ Gen Z fällt eher auf Fake News rein +++ Neuer Komet am Morgenhimmel +++**********Weiterführende Quellen zu dieser Folge:Pilotprojekt Grundeinkommen: kein Rückzug vom Arbeitsmarkt, aber bessere mentale Gesundheit, DIW Wochenbericht, 09.04.2025Zusammenfassung der Studie zum Grundeinkommen auf der Vereinsseite, 09.04.2025Profiling misinformation susceptibility, Personality and Individual Differences, Volume 241, Juli 2025Interconnected Disaster Report 2025, United Nations Press Relaese, 09.04.2025How Climate Change Is Impacting Allergic Rhinitis: A Scoping Review, The Laryngoscope, 09.04.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Ever wonder what it really takes to plan and execute a massive floral event in a ridiculously short timeframe? In this minisode, I'm sharing how I managed to pull off a nearly $40,000 event in just two and a half weeks—during a Minnesota snowstorm, no less!From receiving the call the day after Valentine's Day to sourcing thousands of flowers, coordinating labor, and designing for 62 tables, I'm breaking down exactly how I made it happen (without losing my mind). If you've ever had a last-minute event come in hot, this episode is packed with tips to streamline your process and keep your cool.What You'll Learn:✔️ My go-to process for tackling last-minute large-scale floral events✔️ How to quickly create a design plan based on mood boards and walk-throughs✔️ Where I sourced flowers (including orchids from Thailand & roses from auctions!)✔️ Tools & platforms I used to pull it off (like Komet and Holex)✔️ Why labor planning is just as important as flower ordering✔️ Tips for staying calm and flexible—especially when snowstorms hit during prep!Timestamps:[00:00] The call that kicked off a 40K event with no florist, no plan, and no time[01:00] Mood boards, walk-throughs, and design concepts in 24 hours[02:30] Sourcing vases and building centerpiece tiers[04:00] Getting budget approval + setting expectations[05:15] How I used Holex and Komet to source thousands of stems[07:00] Securing labor and building a time-based staffing plan[08:30] Ordering orchids from Thailand & navigating snowstorm chaos[10:00] Final steps: prepping in-studio, boxing 92 arrangements, and pulling it all off!Resources & Links:

Stačilo rozehrát úvodní partie čtvrtfinále extraligového play off a fanoušci se mají o čem dohadovat, experti o co přít. Emoce znovu budí zákroky, které rozhodčí buď nevidí, nebo pustí, anebo ohodnotí přísněji, než je záhodno. Nejde přitom jenom o neostřeji sledovanou sérii mezi Třincem a Spartou, kde se to kontroverzemi jen hemží a hemžit zřejmě bude. Různorodé ohlasy v éteru mají i duely mezi Kometou a Karlovými Vary. Dost příležitostí pro nový díl podcastu Zimák, kde tentokrát dojde i na ostřejší výměnu názorů mezi Radkem Dudou a Zbyňkem Irglem? Důvod? Zákrok brněnského Kristiána Pospíšila na Víta Jiskru v prvním utkání pod Špilberkem a veškeré okolnosti s ním související. Mikrofony obou expertů dostaly pod návalem zvýšených hlasů dost zabrat, ale nakonec to ustály. Do rozboru expertů Zimáku se dostanou všechny nynější čtvrtfinálové řežby, včetně návyků rozhodčích, s nimiž se v Zimáku ne úplně souhlasí.

Om några år ska sonden Comet Interceptor skickas upp i rymden för att komma nära en förbipasserande komet. Vilken komet det blir, vet man inte förrän då och mötet kommer att gå svindlande snabbt. Lyssna på alla avsnitt i Sveriges Radio Play. Programmet sändes första gången 11/11-2024.På en laboratoriebänk på Ångströmlaboratoriet i Uppsala ligger ett elektronikkort som ska med upp i sonden. Forskaren vid Institutet för Rymdfysik Anders Eriksson berättar om kometernas hemvist i Oorts moln längst ut i solsystemet, och om vilken sorts komet han hoppas att sonden som ska skickas upp 2029 kan sammanträffa med.Programledare: Camilla Widebeckcamilla.widebeck@sverigesradio.seProducent: Lars Broströmlars.brostrom@sverigesradio.se

File Download (11:47 min / 5 MB)

V hokejové extralize je nepřehlédnutelnou personou, značkou Komety. Jakub Flek, mistr světa z Prahy a kapitán brněnského souboru. Respektovaný útočník byl dnes od 11:30 váženým hostem podcastu ZIMÁK ŽIVĚ. „Je skvělé mít v extralize hokejisty, jako jsi ty, nedivil bych, kdyby tě to vyneslo o level výš,“ poslal Flekovi superlativ Jaroslav Bednář, tradiční tvář pondělního Zimáku, sám bývalý vynikající útočník. V podcastu se během hodinky rozebíralo aktuální dění v Kometě, ale i výhled do budoucna. Reprezentační opora se netají, že by jednou ráda zkusila cizinu. „Zatím nemám kam utíkat, ale netajím se, že bych to venku rád zkusil. Nabídka by mi ovšem musela dávat smysl, třeba finskou ligu už díky návratům kluků do extraligy, převyšujeme. Zatím nebylo nic konkrétního na stole a jsem rád, že můžu pokračovat v Kometě, moc si vážím důvěry. Ale upřímně, Švýcarsko by mě ze všech destinací lákalo asi nejvíc,“ přiznává 32letý rychlík.

Im Jahr 1969 entdeckt Swetlana Gerasimenko gemeinsam mit ihrem Kollegen Klim Tschurjumow einen Kometen. Dieser wird mehr als 40 Jahre später zufällig Ziel der ESA-Kometenmission Rosetta – und beschert der ukrainischen Astronomin weltweiten Ruhm. Lorenzen, Dirk www.deutschlandfunk.de, Sternzeit

Sejr over Barcelona, triumf i pokalturneringen, en verdensstjernes hjemkomst og en obskur dopingkarantæne. Det har været en vanvittig uge for Aalborg Håndbold, og spørgsmålet er, om direktør Jan Larsen har fået pulsen langt nok ned til at kunne se tilbage på begivenhederne. Også i tennisverdenen har weekenden budt på dopingnyheder. Verdens bedste mandlige tennisspiller, Jannik Sinner, har accepteret en karantæne på tre måneder efter et forløb, der mildest talt har været forvirrende. Tyvstart kårer også weekendens vindere og tabere, og der er stærke kandidater til begge priser. Chido Obi fik debut for United, Mads P. fik sin første sejr i sæsonen, og så måtte FC Nordsjælland køre hjem fra Aalborg med frossen tæer og en aflyst fodboldkamp. Vært: Emil Schiønning Medvært: Tobias Hansen Medvirkende: Aalborg Håndbold-direktør Jan Larsen og tennisreporter Kresten Mosbæk.

Vielen Dank an alle, die uns auch diesmal wieder so viel spannendes Feedback geschickt haben. Wir besprechen in diesem FeedGAG die Folgen ab GAG477 bis GAG489. Aus Zeitgründen haben wir die Postkarten aufgeteilt, der andere Teil landet im nächsten FeedGAG. Alle Infos zur 500. Folge: https://www.geschichte.fm/allgemein/jubilaeumsfolge-gag500/ /// Podcasts des Monats * MAMMUT - Ein Mord in meiner Familie und meine Suche nach Antworten: https://www.ardaudiothek.de/sendung/mammut-ein-mord-in-meiner-familie-und-meine-suche-nach-antworten/13862515/ * Food Crimes - Was schmeckt dahinter? – https://food-crimes.podigee.io/ /// Tools * GAG Tools – https://gag.tools * Chronologisch Hören – https://docs.google.com/spreadsheets/d/1NTHLJ2dXjYzTl28tmD_aj-8g-lZU00N_I18T0v9nFoo/edit?gid=681791364#gid=681791364 * Zufällige Folgen Bookmarklet: Hier der Code als `copy-paste-fire-and-forget` Version (öffnet neuen Tab): ``` javascript:(()=>{var url="[https://www.geschichte.fm/archiv/](https://www.geschichte.fm/podcast/)";var maxEpisode;var now=new Date();var first=new Date("2015-10-01");var diff=(now.getTime()-first.getTime())/1000; diff/=(60*60*24*7);maxEpisode = Math.abs(Math.round(diff));var episode = Math.floor(Math.random()*maxEpisode);if(episode270){url=" "+url+"gag"+episode;}window.open(url,"_blank");})(); ``` // Museen & Ausstellungen Okinawa Prefectural Museum & Art Museum – Ausstellung zur Geschichte Ryukyus und Okinawas Website des Museums: https://www.museums.pref.okinawa.jp/en/oki_museum Brooke Heritage Museum, Kuching – Über die weißen Rajas von Sarawak Website des Museums: https://www.brookemuseum.com/ Bayerische Staatsbibliothek, München Ausstellung: https://www.bsb-muenchen.de/veranstaltungen-und-ausstellungen/article/farben-japans-holzschnitte-aus-der-sammlung-der-bayerischen-staatsbibliothek-6502/ Sumida Hokusai Museum, Tokio – Alles über Hokusai & Ukiyo-e Offizielle Website: https://hokusai-museum.jp/ British Museum: „The Great Wave and its 111 Versions“ YouTube-Video: https://youtu.be/U_025NB8alw Artikel Japan Times: Warum die Ryukyu-Sprachen vom Aussterben bedroht sind Artikel lesen: https://www.japantimes.co.jp/community/2020/06/15/voices/okinawan-language/ BBC: Der schwierige Status Okinawas in Japan Artikel lesen: https://www.bbc.com/news/world-asia-49182716 Der Halley'sche Komet und die Panik von 1910 NASA-Artikel: https://solarsystem.nasa.gov/asteroids-comets-and-meteors/comets/halley/in-depth/ „Der Jupiter-Effekt“ – Das Pseudowissenschafts-Buch von 1974 Wikipedia-Seite: https://en.wikipedia.org/wiki/The_Jupiter_Effect DailyArt: „How Japanese Woodcuts Were Made“ Artikel lesen: https://www.dailyartmagazine.com/how-japanese-woodcuts-are-made/ Popkultur & Empfehlungen Film „Profound Desires of the Gods“ (1968) IMDb-Seite: https://www.imdb.com/title/tt0063538/ „Europa Universalis IV“ – Three Mountains Achievement Spielinfos auf Paradox: https://www.paradoxinteractive.com/games/europa-universalis-iv/about Dokumentation „The Pen: Mightier Than The Sword“ – Die Geschichte des Kugelschreibers YouTube-Video: https://www.youtube.com/watch?v=w6wCrBqHdxs TV-Serie „Sandokan – Der Tiger von Malaysia“ (1976) – Über Piraten und britische Kolonialherrschaft in Borneo IMDb-Seite: https://www.imdb.com/title/tt0073977/ Film „Edge of the World“ (2021) – James Brooke als Abenteuerfilm mit Jonathan Rhys Meyers Trailer & Infos: https://www.imdb.com/title/tt3006472/ Animationsfilm „Miss Hokusai“ (2015) IMDb-Seite: https://www.imdb.com/title/tt3689910/ Fast Forward Science: Die Ausschreibung läuft noch bis 30. April 2025 https://fastforwardscience.de/ Methodisch inkorrekt! sprechen in ihrer Folge über die IG-Nobelpreise über eine Studie, in der es um die Blauen Zonen geht https://minkorrekt.de/mi328-ig-nobelpreise-2024/

STERNENGESCHICHTEN LIVE TOUR 2025! Tickets unter https://sternengeschichten.live Von der Sonne leuchtet es nicht nur, von dort weht auch der "Sonnenwind". Das hat man lange nicht gelaubt und als Eugene Parker seine Existenz vorhergesagt hat, war man nicht begeistert. Die ganze Geschichte hört ihr in der neuen Folge der Sternengeschichten. Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

The Komet goes operational. What it was like to fly and fight in the Me 163 and survivors (people AND planes!) Want to see images? Patreon.com/WorldofWarbirds Want to watch videos? YouTube Channel Support Me! Thanks!

Im Oktober war der Komet Tsuchinshan-ATLAS abends mit bloßem Auge als diffuser länglicher Fleck am Himmel zu sehen. Länger belichtete Fotos, die einen ausgedehnten Schweif zeigten, weckten leider bei vielen Kometenfans falsche Erwartungen. Lorenzen, Dirk www.deutschlandfunk.de, Sternzeit

Discover the fascinating story of the Messerschmitt Me 163 Komet, the world's first and only operational rocket-powered fighter aircraft. Developed by Germany during World War II, the Me 163 was a revolutionary design that pushed the boundaries of aviation technology. In this video, we explore its development, unique features, combat history, and the many challenges faced by its pilots. Want to hear Part II RIGHT NOW? Patreon.com/WorldofWarbirds Want to see images? Patreon.com/WorldofWarbirds Want to watch videos? YouTube Channel Support Me! Thanks!

Um diese Frage geht es in der heutigen Folge der Sendereihe „Hörer fragen“. Können wir uns vorstellen, dass die Welt untergehen wird? Sind solche Gedanken nur reine Fantasie oder wird die Welt wirklich einmal untergehen? Auch wenn sich unsere Gedanken dagegen sträuben, so müssen wir doch zugeben, dass solche Vorstellungen durchaus realistisch sind. Z.B. raste 1994 ein gewaltiger Komet mit 200.000 km/h auf unser Sonnensystem zu.

Der Komet Elenin wurde 2010 entdeckt, hat für Weltuntergangspanik gesorgt und hat ein Jahr später aufgehört zu existieren. Was dazwischen passiert ist und wie Komet einfach so verschwinden kann, erfahrt ihr in der neuen Folge der Sternengeschichten. Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

Angeschnallt, Kracherlaune. Irgendwas war im Wasser, die Sterne standen absolut zu unseren Gunsten: diese Laune hat es in sich. Hier donnersts, da kehrt der Zunder ein, dort steppen Bären, ein Komet am Podcasthorizont. Geil. Viel Spaß ihr lieben. Grüße aus Aschaffenburg: Chris, Marek und Stenger. Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/proseccolaune

 In this episode of the Passive House Podcast Mary James talks with David Komet about the journey of turning an underutilized urban site into a state-of-the-art pickleball facility designed with sustainability, community value, and innovative engineering at its core.   David shares how a chance proposal led to a pivot from residential development to creating a Passive House-compliant sports venue. From optimizing land use near highways to integrating materials like AAC panels for thermal mass, we dive into the challenges and benefits of high-performance building design.https://www.reimaginebuildings.com/https://passivehouseaccelerator.com/events/reimagine-buildings-biomaterialsThank you for listening to the Passive House Podcast! To learn more about Passive House and to stay abreast of our latest programming, visit passivehouseaccelerator.com. And please join us at one of our Passive House Accelerator LIVE! zoom gatherings on Wednesdays.

Om några år ska sonden Comet Interceptor skickas upp i rymden för att komma nära en förbipasserande komet. Vilket komet det blir, vet man inte förrän då och mötet kommer att gå svindlande snabbt. Lyssna på alla avsnitt i Sveriges Radio Play. På en laboratoriebänk på Ångströmlaboratoriet i Uppsala ligger ett elektronikkort som ska med upp i sonden. Forskaren vid Institutet för Rymdfysik Anders Eriksson berättar om kometernas hemvist i Oorts moln längst ut i solsystemet, och om vilken sorts komet han hoppas att sonden som ska skickas upp 2029 kan sammanträffa med.Programledare: Camilla Widebeckcamilla.widebeck@sverigesradio.seProducent: Lars Broströmlars.brostrom@sverigesradio.se

Astronomie ist schwierig. Vor allem, weil unsere Forschungsobjekte so weit weg sind. Wie wir es trotzdem probiert und geschafft haben, ein bisschen des Universums auf die Erde zu holen, erfahrt ihr in der neuen Folge der Sternengeschichten: Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

Z velkého letenského festivalu zbyly oči pro pláč a zloba fanoušků, napálených klientů. Prosincové Winter Hockey Games zůstaly opět a jenom na papíře, stejně jako předchozí akce ve Špindlerově Mlýně. Slušná munice pro nový díl podcastu Zimák, jehož tradiční hosté Radek Duda se Zbyňkem Irglem měli být součástí akce. Extraligou rezonuje story Jakuba Zbořila, jenž se před týdnem kochal děním na brněnském Výstavišti, kde panuje čilý ruch při stavbě nové multifunkční arény. Za pár dnů už seděl v autě směr Pardubice. Někdejší bek Boston Bruins dal Kometě košem, zbořil sny fanoušků o posile do obrany, na zem spadla i přání vidět bratry Jakuba a Adama v jednom hokejovém triku. Podle informací Zimáku se jeho plat blíží tomu, co má Roman Červenka. Je to adekvátní? A z Motoru se chystá odejít Jáchym Kondelík, proč už teď a ne až po sezoně?

In Folge 115 statten wir dem Kugelsternhaufen Omega Centauri einen Besuch ab. Denn dort hat man das “Missing Link” der schwarzen Löcher entdeckt. Nämlich ein mittelschweres schwarzes Loch, das erklären könnte, wie die gigantischen schwarzen Löcher in den Zentren der Galaxien entstehen. Davor gibt es ein kleines Potpourri an Musik, Science Fiction, Kometen, schlechten Schlagzeilen, Polarlichtern, und so weiter. Evi erzählt vom Film “Gattaca” und wir diskutieren darüber, ob wir uns in Zukunft genetisch verändern müssen, wenn wir ins Weltall wollen und ob es irgendwann einen Homo Galacticus geben wird. Wenn ihr uns unterstützen wollt, könnt ihr das hier tun: https://www.paypal.com/paypalme/PodcastDasUniversum Oder hier: https://steadyhq.com/de/dasuniversum Oder hier: https://www.patreon.com/dasuniversum

Vi er blevet inspireret af den seneste Starship-test til at se nærmere på de helt store raketter, fra Saturn V og frem. Efter mange år med rumfærger og mindre raketter er der nu for alvor ved at være konkurrence på markedet for raketter over 100 meter… I de korte nyheder ser vi på ESAs idé om at ville reparere satellitter, på kommunikationsnetværket Moonlight, og på flotte nye data fra Euclid-missionen. Endelig skal vi selvfølgelig gætte en rumlyd! Lyt med

Was würdest du tun, wenn ein gigantischer Komet auf die Erde zurast und du nur noch 24 Stunden zu leben hättest? Jacob und Gabriel stellen sich dieser Frage – und es wird chaotisch! Bevor der Weltuntergang naht, streiten die beiden erst einmal darüber, wie man richtig Wäsche wäscht: Bunt mit weiß? 30 oder 60 Grad? Und während Jacob eine Agentur plant, um endlich cooler zu werden, eskaliert eine Debatte über Gabriels Wäscheständer. Dazu gibt's Jacobs schräge Beobachtungen aus dem Kindergarten seiner Töchter, inklusive Österreichs Liebe zum Rufzeichen. Gabriel hat eine Astrophysikerin interviewt und bringt uns auf den neuesten Stand: Was passiert, wenn ein Komet wirklich einschlägt? Und was würden die beiden mit auf den Mond nehmen, falls es noch eine Chance zur Rettung gibt? Die Community hat auch mitgemischt – und die Antworten könnten nicht unterschiedlicher sein! Freu dich auf Chaos, Wissenschaft und die große Frage: Wie würdest DU deine letzten 24 Stunden verbringen? Highlights der Folge:

Israels Regierung bestätigt Tod von Yahya Sinwar, Schweizer Rüstungsindustrie wegen Neutralität unter Druck, Republikanische Wahlaufseher im Einsatz gegen die Wahllüge, Komet und Supermond am Schweizer Himmel

Der Komet C/2023 A3 Tsuchinshan-ATLAS lässt gerade viele fasziniert in den Nachthimmel blicken. Man entdeckt ihn mit bloßem Auge. Richtig prächtig erscheint der Komet aber im Fernglas, dem Teleskop und auf Fotos. Denn schon die Handy-Kamera sieht ihn besser als der Mensch. Wie man Kometen, den Mond und Sternbilder schon mit einfachsten Mitteln mit der Kamera einfangen kann, hört Ihr in dieser Podcast-Folge. Feedback? Anregungen? Schreibt uns: WhatsApp (https://wa.me/491746744240) oder iq@br.de.

Ein Komet nähert sich der Erde. Welche unheimliche Macht steuert ihn? Von Tobias Brodowy.

Der Komet C/2023 A3 Tsuchinshan-Atlas nähert sich gerade der Erde. Wenn das Wetter mitspielt, könnte er zwischen dem 12.-14. Oktober hell am Himmel sichtbar werden. Der Komet fliegt seit 80.000 Jahren durchs All. Wie und wo lässt er sich beobachten? Martin Gramlich im Gespräch mit Uwe Gradwohl, SWR-Wissenschaftsredaktion

Stor Mærsk-rival gør indtog på Aarhus Havn. Bankernes image bliver hastigt bedre, særligt Danske Bank. 29-årig fransk komet skal tale til DF's årsmøde. Renterne falder og 3,5 pct.-lånet nærmer sig. Rusland får våben fra Kina. New Yorks borgmester tiltalt for korruption. Vært: Lasse Ladefoged (lala@borsen.dk)

Wo soll Mensch hin, wenn die gesamte Stadt nur noch aus Spekulationsobjekten besteht? Die Kündigung wegen Eigenbedarfs flattert auch bei Eva und Paola ins Haus. Gemeinsam begeben sie sich in die Abgründe der Wohnungssuche in Berlin und stoßen dabei auf eine unterirdische Utopie als Antwort auf den angespannten Wohnungsmarkt. Ein Live-Hörspiel in remote. Mit Friedelise Stutte, Katja Hutko, Yanina Ceron u. v. a.// Realisation Live Love Kollektiv// Eine Autor:innen-Produktion für den rbb 2022

Ivan Martinović hat bei den Rhein-Neckar Löwen eingeschlagen wie ein Komet. Zehn Tore zum Bundesliga-Auftakt gegen Rekordmeister Kiel, dazu die geballte Ladung Balkan-Energie. Über seine Gefühle beim ersten Mal SAP Arena als Löwe, den Kickstart im gelben Trikot, die weiteren Aufgaben und seine bisherige Karriere, über all das spricht der sympathische Kroate mit Wiener Wurzeln und macht den Auftakt in Staffel 6 des Löwenfunk zu einem echten Erlebnis.

Tre raringer møtes for å fekte med rare fakta. Piller mot kometer, store tall og båten som var i flere årstider og århundrer samtidig. Raringer:Halvard Strønen (@havard_s),Even Holm Hansen (@evenhansen97),Andreas Wahl (@andreas__wahl)

Send us a Text Message.Title:

Send us a Text Message.Get ready for a laugh and a good time on this week's episode of 2 Fat Guys Talking Flowers! Our special guest is none other than Dennis Wheeler, the national sales manager for Chrysal USA. Join us as we hear all about Dennis's journey from the nursery to navigating the interview processes of the flower industry. With 30 years of experience in post-harvest sales, Dennis spills the T-Bag on valuing relationships over spreadsheets, shares his top sales tips, and reveals his two "wow" opportunities in the world of flower sales.The team shares the exciting news that all the Freshies & Fatties out there can now snag select Chrysal items on our Komet! And that's not all -  Mike has cooked up a fabulous giveaway where you can score custom flower food packets. Want to know the secret to winning? You'll have to tune in to find out!And if you happen to spot Dennis at SAF don't forget to give him a warm welcome and say the secret word. This episode is bursting with fun stories, valuable insights, and even a little science - don't miss it!Learn more about Chrysal and their products at:  https://www.chrysal.com/en-us

Wir suchen etwas wunderschönes, obwohl es nur aus Eis, Staub und Stein besteht. Das Ding, das wir suchen, ist eher selten. Jedes Jahr entdecken Forscherinnen und Forscher etwa 20 neue. Dafür schauen sie in den Himmel. Und? Weißt du's schon? Was suchen wir? Ich sag' es dir! Infos zu den Werbepartnern: https://weisstdusschon.de/werbepartner Euch gefällt Weißt du's schon? Dann unterstützt meine Arbeit. Danke! Supporter:innen-Abo bei Apple Podcasts: https://apple.co/3FPh19X Supporter:innen-Abo bei Steady: https://steadyhq.com/wds PayPal-Spende: https://bit.ly/3v891w3 Mehr Infos: https://weisstdusschon.de Feedback, Fragen, Rätselwünsche? Schickt mir eine Nachricht für den Podcast: https://weisstdusschon.de/nachricht oder per Mail an christian@weisstdusschon.de ------ Das Rätsel zum Mitlesen ------ Wissenschaft - Sauseklumpen Wir suchen etwas wunderschönes, obwohl es nur aus Eis, Staub und Stein besteht. Das Ding, das wir suchen, ist eher selten. Jedes Jahr entdecken Forscherinnen und Forscher etwa 20 neue. Dafür schauen sie in den Himmel. Mit speziellen Fernrohren, die man auch Teleskope nennt. Am meisten Himmelsgucker gibt es in Japan und Australien. Manchmal sieht man die fliegenden Eisstaubsteine, die wir suchen, sogar mit bloßem Auge. Im Jahr 1997 zum Beispiel, als ich 16 Jahre alt war. Da flog ein Riesenklumpen namens Hale-Bopp am Himmel vorbei. Mehrere Monate war er sichtbar. Dank des Schweifs. Das ist Staub, der von dem gesuchten Himmelskörper abfällt und von der Sonne angestrahlt wird. So entsteht eine Art Leuchtspur am Nachthimmel, die viele Hundert Millionen Kilometer lang sein kann. So werden auch Himmelskörper sichtbar, die weit weg oder eher klein sind. Denn eigentlich ist das, was wir suchen, nur wenige Kilometer groß. Kein Vergleich zum millionenfach größeren Schweif der gesuchten Weltallflitzer. Manche von ihnen flitzen nur einmal vorbei, auf nimmer wiedersehen. Andere kommen regelmäßig zu Besuch ins Sonnensystem und in die Nähe unserer Erde. Allerdings heißt regelmäßig nicht unbedingt oft. Hale-Bopp, der Besucher in meiner Jugend, lässt sich erst in 2400 Jahren wieder blicken. Und? Weißt du's schon? Wie nennt man die Sauseklumpen aus Eis, Staub und Stein, die wir suchen? Ich sag es dir! Es sind: die Kometen!

Wasser ist wichtig. Und es gibt im Universum überraschend viel Wasser. Aber nicht unbedingt so, wie wir uns das vorstellen. Wo es feucht ist im Kosmos, erfahrt ihr in der neuen Folge der Sternengeschichten. Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

Dane and Jacqui discuss the Bean Farmer to Astronaut pipeline. Also, Jax gives us the lowdown on feminism, and Dane discusses what version of Torn is playing when Murtagh is emo-ing all over the place. This episode covers Chapters 42-48 of Inheritance, the third book in the Inheritance Cycle by Christopher Paolini.    How to support us:  Get some of our merch  Support us on Patreon    Where to find us:  Website: isthisjustfantasypod.com TikTok: @isthisjustfantasypod Instagram: @justfantasypod   Contact us:  You can contact us directly at: isthisjustfantasypod@gmail.com   Credits:  Our music was written and performed by Adam Blotner Cover artwork by Neil Kohney Every episode was mixed, shot, and edited by Kevin Davis at the Guerrilla Media Company   Learn more about Christopher Paolini and buy Eragon so you can read along!    Links and sources from this show:  Ednaswap Version of Torn  Natalie Imbruglia Version of Torn Wolfchant by Komet

Der Komet Donati hat 1858 die ganze Welt begeistert. Die Wissenschaft ebenso wie die Kunst, Literatur und sogar einen asiatischen König. Warum der Komet so super war, erfahrt ihr in der neuen Folge der Sternengeschichten: https://astrodicticum-simplex.at/?p=36891 Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten)

Nicole-Reine Lepaute hat im Frankreich des 18. Jahrhunderts mit den wichtigsten Astronomen zusammengearbeitet. Was sie da gemacht hat und warum ihr nicht die Anerkennung zugekommen ist, die sie verdient hat, erfahrt ihr in der neuen Folge der Sternengeschichten: https://astrodicticum-simplex.at/?p=36776 Wer den Podcast finanziell unterstützen möchte, kann das hier tun: Mit PayPal (https://www.paypal.me/florianfreistetter), Patreon (https://www.patreon.com/sternengeschichten) oder Steady (https://steadyhq.com/sternengeschichten) Die "Sternengeschichten Live" kann man das erste Mal am 28. März 2024 in Herten sehen: https://schwarzkaue-herten.de/veranstaltung/sternengeschichten-die-live-premiere-in-unserem-spiralarm-der-galaxie/